Covid-19, the pandemic in Italy will end on April 6: data and algorithms say it

The Covid-19 pandemic in Italy is dirty one April by the 15th. This is said by research by the Department of Physics of Complex Systems E’tv’s Lor’nd University of Budapest. The study of the study on 19 March icola there is an amount of data already already in Italy to predict the final outcome of the process. The data from the province of Hubei have a turisaity with Italians those. The method is based on the analysis of logistics that well not the a macroscopic level. In Italy, the number of victims was 6000 and April 15 2020.

“At the beginning of the epidemic,” the study reads,  Italian data showed the same exponential growth trend observed in Hubei Province, China. The question we have to ask ourselves is this: can the measures taken in Italy stop the exponential growth of infections? Can we reach the threshold of the final saturation shown in China? The daily growth rate of deaths fluctuated in China at around  25-30%  which we could define as the “natural” growth rate in the absence of intervention.  10% The analysis of the Italian data starts from 25 February with a daily growth rate of 20-30%. The blockade of  Lombardy  begins on March 9 with about 463 deaths: the linear trend can be observed from this date. There is therefore also a similar effect in our country with a daily rate of growth that seems to decrease by  4% per 1000 new deaths:the daily growth rate will therefore be reduced from about 24% to zero after 6000 deaths. In Hubei province, the 12% growth rate fell to zero after about 3,000 deaths. This therefore seems to be a universal consequence of the blockade. Using these parameters is then calculated when the spread of the virus in Italy could end. In China the process lasted  39.4 days,  while in Italy, starting from the date of 9 March,  27.49 days will have to be calculated, arriving around  6 April.».

Coronavirus, announcement from Canada: “made a vaccine with organized plants”

A Canadian company has revealed that it has a vaccine for COVID-19 just 20 days before the coronavirus sequence, a unique technology they hope to present and for the approval received and administration of the drug.
Brice Clark, CEO of Medicago, has that equal to clarinella can millions up to 10 doses per month. If the various steps are taken by the regulations, the vaccine will be available as early as November. An Israeli research laboratory has also found a vaccine, but according to Clark of Medicago, it is a reliable one thanks to a technique of trafficking that with the talk that is also in vaccines against seasonal flu. ‘There’s also a lot of work to be said that it’s missing the vaccine but it’s about different technologies. Some are vaccines on RNA or DNA that have not been validated for type of use, yet for Coronavirus.”

Come did Clark’s team create one so fast? Hen eggs were not valid, with the use of the bioreactor intended for protein and protein the vaccine. The traditional production of vaccine production a large amount of: according to Clark, their use is the, a long time and is anything but. Vaccine vaccines vaccines that do not target the virus that they aim to. It involves the insertion into the agrobacterium (soil bacterium) of a genetic sequence that is part of my set-up a produce the protein that can then biological. If the satonument virus mutates, come in the case of COVID-19, with a simple production update of the we will have a vaccine. “This is the fatra between us and the methods that egg eggs,” Clark added, “let’s go get the vaccine or the antibody to propagate the virus.”

At the genetic level, the use of plants and agrobacteria  works faster than eggs and makes the vaccine much easier to produce on a large scale, which, in part, is why the U.S. Army has invested in the company. In 2010, the  Defense Advanced Research Projects Agency put together a 100-million-dollar  program  dubbed Blue Angel to examine new discoveries in vaccine production. A big chunk of that money went to Medicago to build a facility in North Carolina, where it proved to be able to make a vaccine in just 20 days and then quickly increase production. Clark said he was very confident that as soon as they had the permits, they would be able to produce  10 million doses of vaccine per month. The only obstacles are now represented by the regulatory authorities. The company’s production method has not yet been approved by the FDA and will need to pass the scrutiny of some clinical trials before moving on to production.

“Thereis a lot of room for negotiation with the regulators,” Clarkadded,  “I  will not put words in his mouth, I will say that our intention is to move to Phase III by November allowing the vaccine to be made available to the public.”

The confirmation came from Anthony Fauci,director of the National Institute of Allergy and Infectious Disease at the National Institutes of Health. In a speech to the U.S. House Oversight and Reform Committee, he explained that testing for a vaccine, without specifying its manufacturer, would be possible within a few weeks, adding that for general administration the timing ranges from 12 to 18 months.